Equities analysts expect that TESARO, Inc. (NASDAQ:TSRO) will post earnings of ($2.52) per share for the current quarter, Zacks reports. Eight analysts have made estimates for TESARO’s earnings, with estimates ranging from ($3.10) to ($2.02). TESARO posted earnings per share of ($1.28) in the same quarter last year, which indicates a negative year-over-year growth rate of 96.9%. The firm is expected to announce its next earnings report after the market closes on Tuesday, August 8th.

According to Zacks, analysts expect that TESARO will report full year earnings of ($8.69) per share for the current fiscal year, with EPS estimates ranging from ($10.26) to ($7.57). For the next fiscal year, analysts forecast that the firm will post earnings of ($4.19) per share, with EPS estimates ranging from ($7.47) to ($0.57). Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow TESARO.

TESARO (NASDAQ:TSRO) last released its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($2.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.26) by $0.29. The firm had revenue of $3.10 million during the quarter, compared to analyst estimates of $3.84 million. TESARO had a negative return on equity of 96.49% and a negative net margin of 910.35%. The business’s revenue was up 909.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($2.22) EPS.

Several brokerages recently commented on TSRO. BidaskClub cut TESARO from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 19th. Robert W. Baird reissued a “neutral” rating on shares of TESARO in a report on Tuesday, June 6th. Bank of America Corporation reissued a “buy” rating and set a $154.00 target price on shares of TESARO in a report on Tuesday, June 20th. Wedbush raised TESARO to an “outperform” rating and set a $168.00 target price on the stock in a report on Monday, June 5th. Finally, ValuEngine cut TESARO from a “hold” rating to a “sell” rating in a report on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. TESARO currently has an average rating of “Buy” and a consensus target price of $177.54.

In other TESARO news, VP Edward C. English sold 8,500 shares of TESARO stock in a transaction on Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the completion of the sale, the vice president now owns 5,396 shares of the company’s stock, valued at approximately $748,155.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 34.60% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the stock. Botty Investors LLC acquired a new stake in TESARO during the second quarter valued at about $140,000. Meeder Asset Management Inc. acquired a new stake in TESARO during the first quarter valued at about $177,000. BB&T Securities LLC acquired a new stake in TESARO during the second quarter valued at about $222,000. Fox Run Management L.L.C. acquired a new stake in TESARO during the second quarter valued at about $224,000. Finally, World Asset Management Inc acquired a new stake in TESARO during the second quarter valued at about $227,000.

Shares of TESARO (TSRO) opened at 128.59 on Monday. The firm’s market cap is $6.93 billion. The company has a 50 day moving average price of $135.83 and a 200-day moving average price of $150.77. TESARO has a 12-month low of $83.26 and a 12-month high of $192.94.

COPYRIGHT VIOLATION WARNING: “-$2.52 EPS Expected for TESARO, Inc. (NASDAQ:TSRO) This Quarter” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/08/07/2-52-eps-expected-for-tesaro-inc-nasdaqtsro-this-quarter.html.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Get a free copy of the Zacks research report on TESARO (TSRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.